133 related articles for article (PubMed ID: 25673133)
1. Anidulafungin dosing during CRRT: do not underestimate adsorption!
Honore PM; Jacobs R; De Waele E; Spapen HD
Crit Care; 2014 Oct; 18(5):618. PubMed ID: 25673133
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics of anidulafungin during albumin dialysis.
Aguilar G; Azanza JR; Sádaba B; Badenes R; Ferrando C; Delgado C; Hernández J; Parra MA; Puig J; Carbonell JA; Navarro D; Belda FJ
Crit Care; 2014 Mar; 18(2):422. PubMed ID: 25028805
[No Abstract] [Full Text] [Related]
3. Treatment with echinocandins during continuous renal replacement therapy.
González de Molina F; Martínez-Alberici Mde L; Ferrer R
Crit Care; 2014 Mar; 18(2):218. PubMed ID: 25029596
[TBL] [Abstract][Full Text] [Related]
4. Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration.
Aguilar G; Azanza JR; Carbonell JA; Ferrando C; Badenes R; Parra MA; Sadaba B; Navarro D; Puig J; Miñana A; Garcia-Marquez C; Gencheva G; Gutierrez A; Marti FJ; Belda FJ
J Antimicrob Chemother; 2014 Jun; 69(6):1620-3. PubMed ID: 24468868
[TBL] [Abstract][Full Text] [Related]
5. Micafungin at a standard dosage of 100 mg/day achieves adequate plasma exposure in critically ill patients with severe burn injuries.
Asensio MJ; Sánchez M; Galván B; Herrero E; Cachafeiro L; Agrifoglio A; Perales E; Luque S; García-de-Lorenzo A
Intensive Care Med; 2015 Feb; 41(2):371-2. PubMed ID: 25465909
[No Abstract] [Full Text] [Related]
6. EPICO 2.0 PROJECT. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations.
Zaragoza R; Ferrer R; Maseda E; Llinares P; Rodríguez A;
Rev Esp Quimioter; 2014 Sep; 27(3):196-212. PubMed ID: 25229375
[TBL] [Abstract][Full Text] [Related]
7. [Echinocandins in a critically ill patient during continuous venovenous renal replacement].
Aguilar G; Carbonell JA; Ferrando C; Badenes R; Belda FJ
Rev Iberoam Micol; 2012; 29(2):85-9. PubMed ID: 22463783
[TBL] [Abstract][Full Text] [Related]
8. [Candidemia and invasive candidiasis approach in critically ill patients: role of the echinocandins].
Almirante B; Garnacho-Montero J; Maseda E; Candel FJ; Grau S; Guinea J; Moreno I; Muñoz P; Ruiz-Santana S
Rev Esp Quimioter; 2017 Oct; 30(5):355-367. PubMed ID: 28945064
[TBL] [Abstract][Full Text] [Related]
9. [Echinocandins: searching for differences. The example of their use in patients requiring continuous renal replacement therapy].
de la Llama-Celis N; Huarte-Lacunza R; Gómez-Baraza C; Cañamares-Orbis I; Sebastián-Aldeanueva M; Arrieta-Navarro R
Rev Esp Quimioter; 2012 Dec; 25(4):240-4. PubMed ID: 23303253
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue distribution of anidulafungin in rats.
Damle B; Stogniew M; Dowell J
Antimicrob Agents Chemother; 2008 Jul; 52(7):2673-6. PubMed ID: 18443124
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy.
Weiler S; Seger C; Pfisterer H; Stienecke E; Stippler F; Welte R; Joannidis M; Griesmacher A; Bellmann R
Antimicrob Agents Chemother; 2013 Aug; 57(8):4053-7. PubMed ID: 23733471
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials.
Kullberg BJ; Vasquez J; Mootsikapun P; Nucci M; Paiva JA; Garbino J; Yan JL; Aram J; Capparella MR; Conte U; Schlamm H; Swanson R; Herbrecht R
J Antimicrob Chemother; 2017 Aug; 72(8):2368-2377. PubMed ID: 28459966
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis.
Dupont H; Massias L; Jung B; Ammenouche N; Montravers P
J Antimicrob Chemother; 2017 May; 72(5):1429-1432. PubMed ID: 28088767
[TBL] [Abstract][Full Text] [Related]
15. Continuous Renal Replacement Therapy: Reviewing Current Best Practice to Provide High-Quality Extracorporeal Therapy to Critically Ill Patients.
Connor MJ; Karakala N
Adv Chronic Kidney Dis; 2017 Jul; 24(4):213-218. PubMed ID: 28778360
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis.
Dimopoulos G; Paiva JA; Meersseman W; Pachl J; Grigoras I; Sganga G; Montravers P; Auzinger G; Sá MB; Miller PJ; Marček T; Kantecki M; Ruhnke M
Int J Antimicrob Agents; 2012 Dec; 40(6):521-6. PubMed ID: 22998997
[TBL] [Abstract][Full Text] [Related]
17. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers in early treatment of invasive candidiasis.
Rouze A; Poissy J; Sendid B; Nseir S
Hosp Pract (1995); 2018 Dec; 46(5):239-242. PubMed ID: 30139287
[No Abstract] [Full Text] [Related]
19. An open-label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America.
Nucci M; Colombo AL; Petti M; Magana M; Abreu P; Schlamm HT; Sanchez SP
Mycoses; 2014 Jan; 57(1):12-8. PubMed ID: 23710653
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.
Trotman RL; Williamson JC; Shoemaker DM; Salzer WL
Clin Infect Dis; 2005 Oct; 41(8):1159-66. PubMed ID: 16163635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
